Zhaohui L. Arter
Hematology | Oncology
101 The City Drive South
Building 23
Orange, CA 92868
Building 23
Orange, CA 92868
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis.
Journal: Cancer treatment reviews
Published: June 07, 2026
When EGFR meets MET: Dual blockade as the next post-TKI standard?
Journal: Med (New York, N.Y.)
Published: February 10, 2026
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report.
Journal: Lung Cancer (Auckland, N.Z.)
Published: February 09, 2026
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.
Journal: Expert review of anticancer therapy
Published: January 18, 2026
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges.
Journal: Lung Cancer (Auckland, N.Z.)
Published: January 01, 2026
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.
Journal: Lung Cancer (Auckland, N.Z.)
Published: June 23, 2025
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib.
Journal: Lung Cancer (Auckland, N.Z.)
Published: June 14, 2025
MET Tyrosine Kinase Domain Mutations in NSCLC: Expanding the Landscape of Acquired Resistance in Oncogene-Driven Tumors.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 02, 2025
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 24, 2025
Gender and Geographic Characteristics Among Thoracic, GI, and Breast Oncology Editorial Boards: Disparities and Measures to Address Gaps.
Journal: JCO global oncology
Published: February 27, 2025
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).
Journal: Lung Cancer (Auckland, N.Z.)
Published: February 24, 2025
Emotional distress: the hidden barrier to immunotherapy success in advanced non-small cell lung cancer.
Journal: Translational lung cancer research
Published: January 09, 2025
Last Updated: 09/26/2026